Clinical trial · Interventional
Combination Treatment for Advanced Liver Cancer
Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of Bare Stent and Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone
NCT02149771CI-TRIAL-00032589withdrawnPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient funding
Summary
Brief summary (as posted)
The purpose of this study is to determine whether TACE combined endovascular stent implantation confers a survival benefit over TACE alone.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Portal Vein Tumor Invasion | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemoembolization | Procedure | — | UNRESOLVED |
| endovascular stents implantation | Device | — | UNRESOLVED |
| iodine-125 seed strand implantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TACE&Stents
- description
- chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
- interventionNames
- Procedure: chemoembolization
- Device: endovascular stents implantation
- Procedure: iodine-125 seed strand implantation
- type
- ACTIVE_COMPARATOR
- label
- TACE
- description
- Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
- interventionNames
- Procedure: chemoembolization
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the American Association for the Study of Liver Diseases (AASLD) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on CT or MRI; * (2) Child-Pugh classification grade A or B； * （3）Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. Exclusion Criteria: * advanced liver disease (bilirubin levels \>3 mg/dL, ASTor ALT \>5 × upper limit of normal)； * Tumor invade the Inferior Vena Cava, extrahepatic spread; * contraindications for doxorubicin or oxaliplatin chemotherapy; * any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/L or prothrombin activity below 50 %); * renal failure,cardiac ejection fraction \<50 %) or end-stage disease； * patients who were not capable of cooperation during the procedure.
References
Publications (0)
Data not yet available
No reference posted for this study.